Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: “I thought, ‘I hope to God we don’t wind up on ventilators. We have children. Who’s going to raise these kids?”
But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that’s part of an international effort to test an antiviral treatment that could halt covid early in its course.
By the next day, the couple were taking four pills, twice a day. Though they weren’t told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered.
“I don’t know if we got the treatment, but I kind of feel like we did,” Miranda Kelly said. “To have all these underlying conditions, I felt like the recovery was very quick.”
The Kellys have a role in developing what could be the world’s next chance to thwart covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.
“Oral antivirals have the potential to not only curtail the duration of one’s covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick,” said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies.
Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that can shorten the duration of influenza and reduce the risk of hospitalization if given quickly.
The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can’t enter healthy cells, or lower the amount of active virus in the body.
At least three promising antivirals for covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development.
“I think that we will have answers as to what these pills are capable of within the next several months,” Dieffenbach said.
The top contender is a medication from Merck & Co. and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys’ Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.
They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces the patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.
So far, only one antiviral drug, remdesivir, has been approved to treat covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills.
Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration “before year-end.”
Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can [...]
Pioneering Artificial Intelligence (AI) technology, developed by experts at University of the West of Scotland (UWS), is capable of accurately diagnosing Covid-19 in just a few minutes. The groundbreaking program is able to detect [...]
Antimicrobial resistance poses a significant threat to humanity, health leaders have warned, as a study reveals it has become a leading cause of death worldwide and is killing about 3,500 people every day. More [...]
The Necessity of Novel Antiviral Materials With the severe acute respiratory coronavirus 2 (SARS-CoV-2) being highly infectious and transmissible, the need for novel antiviral materials that can decrease viral activities has become paramount. Preparation procedures [...]
Individuals living with Type 1 diabetes must carefully follow prescribed insulin regimens every day, receiving injections of the hormone via syringe, insulin pump or some other device. And without viable long-term treatments, this course [...]
Researchers from the University of Sydney Nano Institute and School of Chemistry have revealed that tiny gas bubbles – nanobubbles just 100 billionths of a metre high – form on surfaces in unexpected situations, [...]
Innovative researchers have investigated the potential of incorporating a gelatin methacryloyl hydrogel functionalized with synthetic nanoclay laponite to improve the delivery of osteoblast derived extracellular vesicles for increased bone repair. This research has been [...]
A couple of essential biomolecules play a key role in the process of blood clotting. One of these is a protein called fibrinogen. It is often given to those who have experienced heavy bleeding, [...]
Nanoemulsions are a relatively new technology that has found significant use for delivering functional chemicals such as micronutrients, flavorings, bioactive molecules, and antimicrobial agents into food and beverage products. This article focuses on applying [...]
Researchers at Penn Medicine have discovered a new, more effective method of preventing the body's own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune [...]
Bioinspired by tunicates and mussels, a Korean research team has created a “bomb-like” anticancer therapeutic agent that only destroys cancer cells. Schematic diagram of the mechanism of action of photoactivatable adhesive nanobombs made with [...]
(Reuters) - “Long COVID”, where symptoms of COVID-19 persist for months after an initial infection, could be emerging as a chronic disease in Finland, Minister of Family Affairs and Social Services Krista Kiuru said [...]
The rising concern of plastic pollution and the increase in nanoplastics, which are small plastic debris particles with nanoscale sizes between 1 and 1000 nm, have become a field of research that has garnered [...]
Exciting and novel research has investigated the internalization of nanoparticles by cells to optimize drug delivery into target cells. This research, published within the journal, Pharmaceutics, aims to analyze the simultaneous uptake of two different [...]
Does the advent of machine learning mean the classic methodology of hypothesize, predict and test has had its day? Isaac Newton apocryphally discovered his second law – the one about gravity – after an [...]
A new approach to brain tumor treatment using photodynamic therapy (PDT) with nanotechnology has been explored in a review published in the journal Biomedicines. Unlike radiotherapy and surgical resection, PDT can treat micro-invasive areas and protect critical [...]